Lori Firestone, NP
Psychiatric/Mental Health · Cleveland, TNNPI 1922145283
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 492 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 492 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$829
- Takeda Pharmaceuticals U.S.A., Inc.$789
- Teva Pharmaceuticals USA, Inc.$687
- plus $4K from 17 others
What the payments were for
- Food & beverage$9,56899%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 69 | $1,368 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,315 |
| Neurocrine Biosciences, Inc. | 61 | $1,100 |
| Alkermes, Inc. | 40 | $829 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $789 |
| Teva Pharmaceuticals USA, Inc. | 38 | $687 |
| Johnson & Johnson | 29 | $573 |
| Lundbeck LLC | 25 | $526 |
| AbbVie | 24 | $455 |
| Vanda Pharmaceuticals Inc. | 22 | $440 |
| Supernus Pharmaceuticals, Inc. | 18 | $378 |
| Sunovion Pharmaceuticals Inc. | 16 | $349 |
| Almatica Pharma LLC | 8 | $153 |
| Idorsia Pharmaceuticals US Inc | 7 | $133 |
| Merck | 4 | $77 |
| Jazz Pharmaceuticals Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| Harmony Biosciences LLC | 3 | $66 |
| Bausch Health US, LLC | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Neos Therapeutics, LP | 2 | $49 |
| Eisai Inc. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
How this compares
$9,624 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 28 | $46,655 |
| RexultiBrexpiprazole | 28 | $39,199 |
| VraylarCariprazine Hcl | 25 | $38,167 |
| TrintellixVortioxetine Hydrobromide | 62 | $33,086 |
| Aripiprazole | 298 | $14,490 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 167 | $11,126 |
| Duloxetine Hcl | 422 | $8,617 |
| Oxcarbazepine | 99 | $5,277 |
| Alprazolam | 1,439 | $4,994 |
| Mirtazapine | 269 | $4,002 |
| Buspirone Hcl | 295 | $3,825 |
| Trazodone Hcl | 358 | $3,607 |
| Paroxetine Hcl | 249 | $3,216 |
| Ziprasidone Hcl | 42 | $3,200 |
| Quetiapine Fumarate | 240 | $3,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,315 | $46,65528 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,368 | $39,19928 claims |
| AbbVieVraylar | $455 | $38,16725 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $789 | $33,08662 claims |
| Almatica Pharma LLCSertraline Hcl | $153 | $1,748263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Cleveland
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
- Kristal HurstBlaine$260K
- Kaitlynn EarlsGreeneville$228K
- Tory WoodardCookeville$191K
- Sarah VogelfangerMemphis$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.